Latest news
Relay Therapeutics (RLAY) Stock Faces Cash Burn Pressure Despite Flat Reaction - simplywall.stsimplywall.st · Sat, 08 Aug 2026 02:33:26 GMTRLAY Maintained by Barclays -- Price Target Raised to $30.00 - GuruFocusGuruFocus · Fri, 07 Aug 2026 21:25:18 GMTFMR LLC (RLAY) discloses 21.27M-share, 10% holding in Relay Therapeutics - Stock TitanStock Titan · Fri, 07 Aug 2026 15:20:47 GMTIs Relay Therapeutics Inc (RLAY) Overvalued After Q2 Earnings Mi - GuruFocusGuruFocus · Fri, 07 Aug 2026 08:20:20 GMTRelay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 23:10:13 GMTRelay Therapeutics Q2 2026 earnings: Clinical spending rises with cash runway into 2029 - TradingKeyTradingKey · Thu, 06 Aug 2026 21:57:44 GMTRelay Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 21:39:47 GMTRelay Therapeutics Q2 revenue misses estimates on higher R&D expenses; net loss widens - TradingViewTradingView · Thu, 06 Aug 2026 20:40:49 GMT